CSA eye drops potentially useful for SEI treatment after AK

Article

Cycloisporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK).

Cyclosporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK), claims a paper featured in Cornea.

A retrospective case series led by Dr Bennie Jeng, Department of Ophthalmology, University of California, San Francisco, California, USA, included patients with symptomatic corneal SEI occurring after AK from 2 institutions. All patients were resistant to tapering of corticosteroid eye drops prior to administration of CSA drops.

Basic demographic data, involved eyes, duration of symptoms, initial best spectacle-corrected visual acuity (BSCVA), types of corticosteroid administered, clinical course and best spectacle-corrected visual acuity at the final follow-up visit.

Symptomatic SEI after AK, that was resistant to tapering but responsive to corticosteroid eye drops, was found in 12 eyes of 7 patients. The corticosteroid eye drops could be tapered after the administration of CSA eye drops.

It was found that all eyes could generally be maintained on CSA drops for once a day or less. However, the research suggests further study into the use of CSA drops in treating SEI.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.